Trial · NCT06107738
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
NCT06107738, Phase 2, Recruiting, Barbara Ann Karmanos Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma. Trials, record NCT06107738. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06107738
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- NCT number
- NCT06107738
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Daratumumab/rHuPH20 Co-formulation
- First posted
- 2023-10-30
- Last updated
- 2026-06-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of MRD (-) at 12 months | 12 months | Summarized by a binomial response rate and its associated 2-sided 90% confidence interval (CI) using Pearson-Klopper method. |
| Secondary | Rate of Sustained MRD (-) | 24 months | The rate at which IMWG (International Myeloma Working Group) response category improves by at least one grade during maintenance and the rate of treatment interruptions and dosage adjustments during maintenance will be summarized by a binomial response rate and 2-sided 95% CI using Pearson-Klopper method. Two or more consecutive negative measurements during therapy which are at least 6 months apart. |
| Secondary | Progression-Free Survival | 12 months | Duration from the start date of treatment until the date of progression (as defined by IMWG criteria) or death from any cause. |
| Secondary | Progression Free Survival | 24 months | Duration from the start date of treatment until the date of progression (as defined by IMWG criteria) or death from any cause. |
| Secondary | Overall Survival | 12 months | Duration from the start date of treatment until the date of death from any cause |
| Secondary | Overall Survival | 24 months | Duration from the start date of treatment until the date of death from any cause |
| Secondary | Rate on Improvement in IMWG response category | 24 months | Rate at which IMWG response category improves by at least 1 grade |
| Secondary | Frequency of treatment interruptions and dosage adjustments during maintenance | 24 months | Frequency of treatment interruptions and dosage adjustments during maintenance. |
| Secondary | Patient reported Quality of Life (QoL) per EORTC QLQ-C30 | At baseline and day 1 of each treatment cycle until end of treatment | The 30 question European Organization for Research and Treatment, Quality of Life Questionnaire for cancer patients (EORTC QLQ-C30) is a 30-item subject self-reported questionnaire composed of both multi-item and single scales. The EORTC QLQ-C30 questionnaire is scored using a four-point Likert scale. The scores are then transformed to a scale of 0 to 100, where higher scores indicate better quality of life. The questionnaire includes five functions, nine symptoms, and a global health status. |
| Secondary | Patient reported Quality of Life (QoL) per EQ-5D-5L | At baseline and day 1 of each treatment cycle until end of treatment | The European Organization for Research and Treatment EuroQol (EORTC EQ-5D-5L) questionnaire is a patient reported health-related quality of life questionnaire that consists of two parts: The first part is the EQ-5D descriptive system that measures the respondent's health status in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Items are rated 1=No problem, 2=Slight Problem, 3=Moderate Problem, 4=Severe Problem and 5=Extreme Problem or inability. Part 2 is the EQ visual analogue scale (EQ VAS) records the respondent's overall current health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06107738
GET https://conductscience.org/api/trials/v1/NCT06107738/registered